Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortizatization of IntangiblesCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Xeris Biopharma Holdings (XERS) Change in Accured Expenses (2020 - 2025)

Xeris Biopharma Holdings (XERS) has disclosed Change in Accured Expenses for 6 consecutive years, with $4.1 million as the latest value for Q4 2025.

  • For the quarter ending Q4 2025, Change in Accured Expenses fell 3.1% year-over-year to $4.1 million, compared with a TTM value of $3.7 million through Dec 2025, up 2.0%, and an annual FY2025 reading of $3.7 million, up 2.0% over the prior year.
  • Change in Accured Expenses was $4.1 million for Q4 2025 at Xeris Biopharma Holdings, up from $2.8 million in the prior quarter.
  • Across five years, Change in Accured Expenses topped out at $15.6 million in Q2 2023 and bottomed at -$13.9 million in Q1 2023.
  • Average Change in Accured Expenses over 5 years is $141900.0, with a median of -$299000.0 recorded in 2023.
  • Peak annual rise in Change in Accured Expenses hit 1594.69% in 2025, while the deepest fall reached 1172.62% in 2025.
  • Year by year, Change in Accured Expenses stood at -$1.2 million in 2021, then soared by 500.56% to $5.0 million in 2022, then tumbled by 245.83% to -$7.3 million in 2023, then surged by 158.29% to $4.3 million in 2024, then dropped by 3.1% to $4.1 million in 2025.
  • Business Quant data shows Change in Accured Expenses for XERS at $4.1 million in Q4 2025, $2.8 million in Q3 2025, and $5.4 million in Q2 2025.